Francois Ghiringhelli
Overview
Explore the profile of Francois Ghiringhelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
394
Citations
24664
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roussot N, Kaderbhai C, Ghiringhelli F
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075753
Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Immunotherapy targeting the PD-1/PD-L1 axis has revolutionized treatment, providing durable responses in a subset of patients. However, with...
2.
Talpin A, Maia A, Carpier J, Kulakowski G, Aubergeon L, Kervevan J, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39979071
Background: Molecular mimicry between commensal bacterial antigens and tumor-associated antigens (TAAs) has shown potential in enhancing antitumor immune responses. This study leveraged this concept using commensal bacterial antigens, termed OncoMimics,...
3.
Bellio H, Roussot N, Bertaut A, Hervieu A, Zanetta S, Tharin Z, et al.
Future Oncol
. 2025 Feb;
21(6):699-706.
PMID: 39913183
Purpose: A phase I study of FOLFIRINOX3-bevacizumab (bFOLFIRINOX3)defined the RP2D for irinotecan at 70 mg/m² and showed promising activity. This phase II trial aimed to evaluate the efficacy of bFOLFIRINOX-3...
4.
Schmauch B, Cabeli V, Domingues O, Le Douget J, Hardy A, Belbahri R, et al.
iScience
. 2025 Jan;
28(1):111638.
PMID: 39868035
Over the last decade, Hippo signaling has emerged as a major tumor-suppressing pathway. Its dysregulation is associated with abnormal expression of and -family genes. Recent works have highlighted the role...
5.
Thibaudin M, Roussot N, Burlot C, Schmitt A, Vincent J, Tharin Z, et al.
Signal Transduct Target Ther
. 2025 Jan;
10(1):22.
PMID: 39820336
In the tumour microenvironment, IL-1α promotes neoangiogenesis, matrix remodelling, tumour proliferation, chemoresistance, and metastases. Highly expressed in human colorectal cancers, IL-1α is associated with poor prognosis. XB2001, a fully human...
6.
Fourrier T, Truntzer C, Peroz M, Derangere V, Vincent J, Bengrine-Lefevre L, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796718
Background/objectives: Metastatic colorectal cancer (mCRC) is mainly treated with 5-Fluoro-Uracil (5-FU), Oxaliplatin and Irinotecan chemotherapies and anti-Epidermal Growth Factor Receptor (EGFR) or anti-Vascular Endothelial Growth Factor (VEGF) targeted therapies. Due...
7.
Fournier C, Mercey-Ressejac M, Derangere V, Al Kadi A, Rageot D, Charrat C, et al.
EBioMedicine
. 2025 Jan;
112:105543.
PMID: 39793480
Background: mRNA-based cancer vaccines show promise in triggering antitumour immune responses. To combine them with existing immunotherapies, the intratumoral immune microenvironment needs to be deeply characterised. Here, we test nanostructured...
8.
Truntzer C, Ouahbi D, Huppe T, Rageot D, Ilie A, Molimard C, et al.
Biomedicines
. 2025 Jan;
12(12.
PMID: 39767661
: Pancreatic ductal adenocarcinoma (PDAC) is a cancer with very poor prognosis despite early surgical management. To date, only clinical variables are used to predict outcome for decision-making about adjuvant...
9.
Rolfo C, Greillier L, Veillon R, Badin F, Ghiringhelli F, Isambert N, et al.
JTO Clin Res Rep
. 2024 Dec;
6(1):100748.
PMID: 39717667
Introduction: In a phase 1 study, bintrafusp alfa was found to have an encouraging clinical activity in patients with previously treated advanced NSCLC. This study evaluated the safety and efficacy...
10.
Matheux A, Collas L, Grisard M, Goulaieff L, Ghiringhelli F, Bengrine-Lefevre L, et al.
Cancer Chemother Pharmacol
. 2024 Dec;
95(1):9.
PMID: 39702680
Objectives: The use of plasma uracil measurements to detect dihydropyrimidine dehydrogenase (DPD) deficiency is one of the methods for preventing toxicities associated with fluoropyrimidines, including 5-Fluorouracil (5-FU). Unfortunately, this measurement...